Concepedia

Publication | Open Access

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma

22

Citations

23

References

2023

Year

Abstract

Our data demonstrate the preclinical justification for studying the benefit of dual PARP and HDAC inhibition in the treatment of Ewing sarcoma in a clinical trial and provides proof-of-concept for a bifunctional single-molecule therapeutic strategy.

References

YearCitations

Page 1